JP7637827B2 - 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 - Google Patents

疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 Download PDF

Info

Publication number
JP7637827B2
JP7637827B2 JP2024505546A JP2024505546A JP7637827B2 JP 7637827 B2 JP7637827 B2 JP 7637827B2 JP 2024505546 A JP2024505546 A JP 2024505546A JP 2024505546 A JP2024505546 A JP 2024505546A JP 7637827 B2 JP7637827 B2 JP 7637827B2
Authority
JP
Japan
Prior art keywords
compounds
formula
present
ring
aromatic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024505546A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023006893A5 (https=
JP2024528127A5 (https=
JP2024528127A (ja
Inventor
ブレック，アン ドゥ
ジャンヌ マリー メネット，クリステル
Original Assignee
コンフォ セラピューティクス エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンフォ セラピューティクス エヌ．ベー． filed Critical コンフォ セラピューティクス エヌ．ベー．
Publication of JP2024528127A publication Critical patent/JP2024528127A/ja
Publication of JPWO2023006893A5 publication Critical patent/JPWO2023006893A5/ja
Publication of JP2024528127A5 publication Critical patent/JP2024528127A5/ja
Priority to JP2025023227A priority Critical patent/JP7836437B2/ja
Application granted granted Critical
Publication of JP7637827B2 publication Critical patent/JP7637827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2024505546A 2021-07-30 2022-07-28 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 Active JP7637827B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023227A JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163227552P 2021-07-30 2021-07-30
US202163227555P 2021-07-30 2021-07-30
US63/227,552 2021-07-30
US63/227,555 2021-07-30
PCT/EP2022/071231 WO2023006893A1 (en) 2021-07-30 2022-07-28 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023227A Division JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Publications (4)

Publication Number Publication Date
JP2024528127A JP2024528127A (ja) 2024-07-26
JPWO2023006893A5 JPWO2023006893A5 (https=) 2025-01-17
JP2024528127A5 JP2024528127A5 (https=) 2025-01-17
JP7637827B2 true JP7637827B2 (ja) 2025-02-28

Family

ID=83149285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024505546A Active JP7637827B2 (ja) 2021-07-30 2022-07-28 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物
JP2025023227A Active JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023227A Active JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Country Status (16)

Country Link
US (1) US20240368133A1 (https=)
EP (1) EP4377307A1 (https=)
JP (2) JP7637827B2 (https=)
KR (1) KR20240063881A (https=)
AU (2) AU2022318349B2 (https=)
CA (1) CA3227194A1 (https=)
CL (1) CL2024000230A1 (https=)
CO (1) CO2024000880A2 (https=)
CR (1) CR20240041A (https=)
DO (1) DOP2024000017A (https=)
EC (1) ECSP24007288A (https=)
IL (1) IL310330A (https=)
JO (1) JOP20240019A1 (https=)
MX (1) MX2024001155A (https=)
PE (1) PE20241304A1 (https=)
WO (1) WO2023006893A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025084799A (ja) * 2021-07-30 2025-06-03 コンフォ セラピューティクス エヌ．ベー． 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3254395A1 (en) 2022-05-17 2023-11-23 Eli Lilly And Company AT2R'S ANTAGONISTS AND THEIR USES
WO2024199402A1 (zh) * 2023-03-29 2024-10-03 武汉人福创新药物研发中心有限公司 一种作为at2r拮抗剂的杂环化合物
TW202502346A (zh) * 2023-06-16 2025-01-16 大陸商武漢人福創新藥物研發中心有限公司 作為at2r拮抗劑的雜環化合物及其用途
TW202515864A (zh) * 2023-10-10 2025-04-16 大陸商武漢人福創新藥物研發中心有限公司 一種at2r拮抗劑及其用途
WO2025180473A1 (zh) * 2024-02-29 2025-09-04 上海汇伦医药股份有限公司 含四唑类化合物、其药物组合物及其用途

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510831A (ja) 1997-07-21 2001-08-07 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ アシル−ピペラジニル−ピリミジン誘導体、その製法および医薬としての応用
JP2002512229A (ja) 1998-04-20 2002-04-23 ビーエーエスエフ アクチェンゲゼルシャフト カルパインインヒビターとしての複素環式的に置換されたアミド
JP2003501424A (ja) 1999-06-04 2003-01-14 アルミラル・プロデスフアルマ・エス・エイ 抗ヒスタミンおよび抗アレルギー剤としてのインドリルピペリジン誘導体
WO2004089918A1 (ja) 2003-04-09 2004-10-21 Japan Tobacco Inc. 複素芳香５員環化合物及びその医薬用途
JP2009502859A (ja) 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー インドール−３−イル−カルボニル−ピペリジン及びピペラジン誘導体
WO2012033144A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 ピラゾロキノリン化合物
JP2012171868A (ja) 2011-02-17 2012-09-10 Tsutomu Takeuchi Ｎ−ヘテロアリールピペラジン誘導体を有効成分とするｂａｆｆの結合阻害剤
JP2016517411A (ja) 2013-03-14 2016-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グリコシダーゼ阻害剤
WO2016154075A1 (en) 2015-03-20 2016-09-29 Vertex Pharmaceuticals Incorporated Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway
JP2017522346A (ja) 2014-08-01 2017-08-10 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
WO2018057588A1 (en) 2016-09-21 2018-03-29 Vertex Pharmaceuticals Incorporated Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway
JP2019513697A (ja) 2016-03-04 2019-05-30 ヴァンダービルト ユニバーシティー 置換インドールＭｃｌ−１阻害剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU183178B (en) * 1979-07-13 1984-04-28 Thomae Gmbh Dr K Process for preparing new carboxylic acid derivatives
JPH07509464A (ja) * 1992-07-17 1995-10-19 メルク　エンド　カンパニー　インコーポレーテッド 置換ビフェニルメチルイミダゾピリジン
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
JPH09208570A (ja) * 1995-07-10 1997-08-12 Senju Pharmaceut Co Ltd ベンジルピペラジン誘導体
CA2180190A1 (en) * 1995-07-10 1997-01-11 Kazumi Ogata Benzylpiperazine derivatives
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
PT1830869E (pt) 2004-12-24 2013-08-22 Spinifex Pharm Pty Ltd Método de tratamento ou profilaxia
NZ630908A (en) 2013-07-08 2017-08-25 Novartis Ag Heterocyclic compounds and methods of their use
AR108906A1 (es) * 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
AU2019236882B2 (en) 2018-03-23 2023-08-10 Beijing Tide Pharmaceutical Co., Ltd. Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
KR20210097734A (ko) 2018-11-28 2021-08-09 하. 룬드벡 아크티에셀스카브 Magl 저해제에 의해 질병을 치료하는 방법
WO2023006893A1 (en) * 2021-07-30 2023-02-02 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510831A (ja) 1997-07-21 2001-08-07 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ アシル−ピペラジニル−ピリミジン誘導体、その製法および医薬としての応用
JP2002512229A (ja) 1998-04-20 2002-04-23 ビーエーエスエフ アクチェンゲゼルシャフト カルパインインヒビターとしての複素環式的に置換されたアミド
JP2003501424A (ja) 1999-06-04 2003-01-14 アルミラル・プロデスフアルマ・エス・エイ 抗ヒスタミンおよび抗アレルギー剤としてのインドリルピペリジン誘導体
WO2004089918A1 (ja) 2003-04-09 2004-10-21 Japan Tobacco Inc. 複素芳香５員環化合物及びその医薬用途
JP2009502859A (ja) 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー インドール−３−イル−カルボニル−ピペリジン及びピペラジン誘導体
WO2012033144A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 ピラゾロキノリン化合物
JP2012171868A (ja) 2011-02-17 2012-09-10 Tsutomu Takeuchi Ｎ−ヘテロアリールピペラジン誘導体を有効成分とするｂａｆｆの結合阻害剤
JP2016517411A (ja) 2013-03-14 2016-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グリコシダーゼ阻害剤
JP2017522346A (ja) 2014-08-01 2017-08-10 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
WO2016154075A1 (en) 2015-03-20 2016-09-29 Vertex Pharmaceuticals Incorporated Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway
JP2019513697A (ja) 2016-03-04 2019-05-30 ヴァンダービルト ユニバーシティー 置換インドールＭｃｌ−１阻害剤
WO2018057588A1 (en) 2016-09-21 2018-03-29 Vertex Pharmaceuticals Incorporated Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2010年，vol. 20，pp. 26-30

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025084799A (ja) * 2021-07-30 2025-06-03 コンフォ セラピューティクス エヌ．ベー． 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Also Published As

Publication number Publication date
JP2025084799A (ja) 2025-06-03
DOP2024000017A (es) 2024-06-16
AU2022318349B2 (en) 2025-12-18
MX2024001155A (es) 2024-07-01
EP4377307A1 (en) 2024-06-05
ECSP24007288A (es) 2024-04-30
CA3227194A1 (en) 2023-02-02
CR20240041A (es) 2024-06-04
JP7836437B2 (ja) 2026-03-26
KR20240063881A (ko) 2024-05-13
CL2024000230A1 (es) 2024-08-23
AU2025271263A1 (en) 2025-12-18
JOP20240019A1 (ar) 2024-01-30
IL310330A (en) 2024-03-01
PE20241304A1 (es) 2024-06-24
CO2024000880A2 (es) 2024-04-29
AU2022318349A1 (en) 2024-02-15
JP2024528127A (ja) 2024-07-26
WO2023006893A1 (en) 2023-02-02
US20240368133A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
JP7637827B2 (ja) 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物
EP3788038B1 (en) Kras g12c inhibitors and methods of using the same
AU2021245150B2 (en) KRAS G12C inhibitors and methods of using the same
KR101847698B1 (ko) 브로모도메인 저해제로서의 벤지미다졸론 유도체
AU2015271837B2 (en) Tank-binding kinase inhibitor compounds
AU2015252654B2 (en) Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors
IL267495A (en) Kras g12c inhibitors and methods of using them
EP2763533B1 (en) Triazolyl pde10 inhibitors
AU2013312477A1 (en) Compounds and methods for kinase modulation, and indications therefor
RS57117B1 (sr) Jedinjenja i metode modulacije kinaze i povezane indikacije
AU2016333508A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors
AU2012318874A1 (en) 1,3-substituted azetidine PDE10 inhibitors
JP2018509377A (ja) 生体アミン輸送モジュレータとしてのヘテロ環式化合物
JP2022533710A (ja) Ｎを含むヘテロアリール誘導体およびこれを有効成分として含むがんの予防または治療用薬学的組成物
CA3248820A1 (en) COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND RELATED INDICATIONS
CN120917011A (zh) 异吲哚啉衍生物和苯并吲哚衍生物及其应用
CN118159530A (zh) 用于治疗疼痛、特别是神经性疼痛和/或与at2r和/或at2r介导的信号传导相关的其它疾病或障碍的化合物
AU2024284667A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
TWI690528B (zh) 稠環雙環吡啶基衍生物
HK1236197A1 (en) Tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250217

R150 Certificate of patent or registration of utility model

Ref document number: 7637827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150